文献速递外周动脉疾病

药物涂层球囊与普通球囊治疗膝下动脉病变的随机对照研究

Drug-Coated Balloon Angioplasty Compared With Uncoated Balloons in the Treatment of Infrapopliteal Artery Lesions (AcoArt II-BTK).
PubMed 文献 · J Endovasc Ther · 2020-10-29

AcoArt II-BTK 研究前瞻性纳入 120 例慢性肢体威胁性缺血患者,随机接受药物涂层球囊(DCB,n=61)或普通球囊(n=59)治疗膝下原发或再狭窄病变。6 个月造影原发通畅率 DCB 组 75.0% 显著高于对照组 28.3%(p<0.001),晚期管腔丢失更低;12 个月免于临床驱动靶病变血运重建率 DCB 组 91.5% 优于对照组 76.8%(p=0.03),死亡率无显著差异。

要点

  • DCB 治疗膝下病变 6 个月原发通畅率显著优于普通球囊(75.0% vs 28.3%)。
  • DCB 组 12 个月免于 CD-TLR 率更高(91.5% vs 76.8%,p=0.03)。
  • 两组 12 个月死亡率无显著差异(1.7% vs 3.6%,p=0.53)。

核心结论

  • Litos/Tulip 药物涂层球囊治疗膝下病变安全有效,造影和临床结局均优于普通球囊。
  • DCB 原发通畅率显著更高且 CD-TLR 更少,1 年随访安全性不劣于普通球囊。

研究设计与样本

  • 前瞻性、多中心、随机对照研究 AcoArt II-BTK(NCT02137577),纳入 120 例慢性肢体威胁性缺血患者。
  • 随机分为 DCB 组(n=61,平均年龄 70.7±7.4 岁,男性 36 例)和普通球囊组(n=59,平均年龄 70.8±9.0 岁,男性 36 例)。
  • 两组基线临床和靶病变特征无显著差异,靶病变长度 DCB 组 169.95±86.35 mm,对照组 179.93±80.16 mm,约四分之三病变为慢性完全闭塞。

主要发现

  • 6 个月造影原发通畅率 DCB 组 75.0%,对照组 28.3%(p<0.001)。
  • 晚期管腔丢失 DCB 组 0.43±0.62 mm,对照组 0.99±0.55 mm(p<0.001)。
  • 12 个月免于 CD-TLR 率 DCB 组 91.5%,对照组 76.8%(p=0.03)。
  • 12 个月死亡率 DCB 组 1.7%,对照组 3.6%(p=0.53),无显著差异。

关键数值与推荐

  • 6 个月原发通畅率:DCB 75.0% vs 普通球囊 28.3%(p<0.001)。
  • 晚期管腔丢失:DCB 0.43±0.62 mm vs 普通球囊 0.99±0.55 mm(p<0.001)。
  • 12 个月免于 CD-TLR 率:DCB 91.5% vs 普通球囊 76.8%(p=0.03)。
  • 12 个月死亡率:DCB 1.7% vs 普通球囊 3.6%(p=0.53)。

临床怎么用

  • 对于慢性肢体威胁性缺血合并膝下原发或再狭窄病变,可优先考虑使用 Litos/Tulip 药物涂层球囊以提高通畅率。
  • DCB 可减少 12 个月内临床驱动的靶病变血运重建,且 1 年安全性不劣于普通球囊。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare the safety and efficacy of drug-coated balloon (DCB) vs uncoated balloon angioplasty in the treatment of de novo and restenotic infrapopliteal lesions in patients with chronic limb-threatening ischemia (CLTI). MATERIALS AND METHODS: The prospective, multicenter, randomized study AcoArt II-BTK study (ClinicalTrials.gov identifier NCT02137577) enrolled 120 patients who were randomly assigned to angioplasty with either a DCB (n=61; mean age 70.7±7.4 years; 36 men) or a conventional balloon catheter (n=59; mean age 70.8±9.0 years; 36 men). There were no significant differences observed in baseline clinical or target lesion characteristics between the groups. The target lesion length was 169.95±86.35 mm in the DCB group vs 179.93±80.16 mm in the control group, and approximately three-quarters of the lesions were chronic occlusions. Primary patency was assessed by angiography at 6 months, and mortality and clinically-driven target lesion revascularization (CD-TLR) were evaluated at 12 months. RESULTS: Primary patency at 6 months was 75.0% in the DCB group and 28.3% in the control group (p<0.001), while late lumen loss was 0.43±0.62 mm for DCBs vs 0.99±0.55 mm for controls (p<0.001). Freedom from CD-TLR at 12 months was 91.5% in the DCB group vs 76.8% in the controls (p=0.03); there was no significant difference in mortality (1.7% DCB vs 3.6% controls; p=0.53). CONCLUSION: This study demonstrated that the Litos/Tulip DCBs are safe and effective in treating infrapopliteal lesions, with improved angiographic and clinical outcomes vs plain balloon angioplasty. The DCBs demonstrated significantly higher primary patency with fewer CD-TLRs than conventional angioplasty. The safety of the DCBs was noninferior to that of the uncoated balloons after 1 year of follow-up.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Jia X, Zhuang B, Wang F, et al. Drug-Coated Balloon Angioplasty Compared With Uncoated Balloons in the Treatment of Infrapopliteal Artery Lesions (AcoArt II-BTK). J Endovasc Ther. 2020. PMID: 33118432. doi:10.1177/1526602820969681

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。